Clinical Trials · NCT02168491
Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Medical University of Vienna
- Enrollment
- 10
- Start date
- Nov 2014
- Locations
- 1 site, Austria
- Primary endpoint
- Change in HbA1c From Baseline to End